DDInter1628 DDInter347
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Prasugrel
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Anagrelide
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) downregulates {v} (Gene) CPSF4
CPSF4 {u} (Gene) is upregulated by {v} (Compound) Anagrelide
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) downregulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is downregulated by {v} (Compound) Anagrelide
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib {u} (Compound) upregulates {v} (Gene) C10orf2
C10orf2 {u} (Gene) is downregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Anagrelide (Compound) and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) downregulates CPSF4 (Gene) and CPSF4 (Gene) is upregulated by Anagrelide (Compound) and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is downregulated by Anagrelide (Compound) and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ruxolitinib (Compound) upregulates C10orf2 (Gene) and C10orf2 (Gene) is downregulated by Treprostinil (Compound) and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile